Title Page

Title: Autonomic Neuropathies

Authors: Divpreet Kaur, MD[1], Harmanpreet Tiwana, MD[2], Amro Stino*, MD[3], Paola

Sandroni, MD[4]

Author Affiliations:

[1]Penn State College of Medicine, Department of Neurology, Hershey, PA

[2]Dartmouth-Hitchcok Medical Center, Department of Neurology, Lebanon, NH
[3]University of Michigan School of Medicine, Department of Neurology, Division of
Neuromuscular Medicine, Ann Arbor, MI, USA 48109
[4]Department of Neurology, Mayo Clinic, Rochester, MN, USA

Abstract word count: 146

Word count: 5636

*Corresponding author: Amro Stino, MD, University of Michigan School of Medicine,
Department of Neurology, Division of Neuromuscular Medicine, Ann Arbor, MI, USA 48109,
amstino@med.umich.edu

Running Title: Autonomic Neuropathies

Ethical Statement:

We confirm that we have read the Journal's position on issues involved in ethical publication and
affirm that this report is consistent with those guidelines.

Disclosures:

DK, HT, AS, and PS have no relevant conflicts of interest to disclose.

Title: Autonomic Neuropathies

Abstract: Autonomic neuropathies represent a complex group of disorders that preferentially target autonomic fibers and can be classified as either acute/subacute or chronic in onset. Acute-onset autonomic neuropathies manifest with such conditions as paraneoplastic syndromes, Guillain Barre syndrome, Sjögren's syndrome, infection, or toxins/chemotherapy. When the presentation is acute, immune-mediated, and without a secondary cause, autoimmune autonomic ganglionopathy is likely, and should be considered for immunotherapy. Of the chronic-onset forms, diabetes is the most widespread and disabling, with autonomic impairment portending increased mortality and cardiac wall remodeling risk. Acquired light chain (AL) and transthyretin (TTR) amyloidosis represent two other key etiologies, with TTR amyloidosis now amenable to newly-approved gene-modifying therapies. The COMPASS-31 questionnaire is a validated outcome measure that can be used to monitor autonomic severity and track treatment response. Symptomatic treatments targeting orthostatic hypotension, among other symptoms, should be individualized and complement disease-modifying therapy, when possible.

Introduction

The autonomic nervous system regulates a diverse group of biologic functions mediated by the parasympathetic and sympathetic systems. Disturbances that solely or predominantly affect this system are classified as autonomic disorders, and can be of central or peripheral nervous system origin, or both. Autonomic disorders manifest with a myriad of symptoms, ranging from cardiovascular (hypotension, tachycardia) to gastrointestinal (bloating, early satiety, constipation) to genitourinary (neurogenic bladder, erectile dysfunction) to secretomotor (anhidrosis) to pupillomotor (blurred vision, light sensitivity), among others. In this article, we limit our review to autonomic disorders that are peripheral in origin, henceforth referred to as autonomic neuropathies. In light of improved non-invasive autonomic reflex testing, more nuanced understanding of immunopathogenesis, and better classification and testing of hereditary forms of autonomic neuropathy, autonomic neuropathies now are much better understood and classified. Multiple schemata exist to classify autonomic neuropathies. For ease of classification, autonomic neuropathies can be defined temporally as pertains to disease onset

(*acute/subacute vs chronic in onset*), etiologically (*acquired vs hereditary)*, or spatially (*focal vs generalized, sympathetic vs parasympathetic predominant)*, although these divisions are by no means absolute. In our current review, and in line with prior reviews, we adopt a temporal classification schema, first reviewing autonomic neuropathies with an acute/subacute onset and then those with a chronic onset,[1,2] although other approaches exist.[3] We also briefly touch on postural tachycardia syndrome (PoTS). We assume that the reader is familiar with basic findings and interpretation of autonomic reflex testing, which is beyond the scope of this review, but is discussed extensively elsewhere.[4] Furthermore, we focus our review primarily on outpatient evaluation and management. In addition to providing an abbreviated review of the various disease categories, we highlight recent advances in our understanding, where appropriate. Our goal is to provide a practical reference to guide the practicing clinician to evaluate, diagnose, and manage autonomic neuropathies.

Autonomic Neuropathies with an Acute to Subacute Onset

<u>Autoimmune Autonomic Ganglionopathy</u>

AAG is an immune mediated disorder that involves the antibody-mediated targeting of autonomic nerve fibers or ganglia, and is characterized by a triad of orthostatic hypotension, anhidrosis, and severe gastrointestinal (GI) dysmotility.[5,6] 50% of patients carry a ganglionic (α-3 type) nicotinic acetylcholine receptor antibody (gAChR), with titers greater than 1.0nmol/L deemed as quite specific for this condition.[7-9] Furthermore, although classified as acute in onset,

AAG can also be subacute or chronic in presentation.[10] Patients are typically young and healthy, with a slight female preponderance (up to 65% of all cases). Patients have disproportionate GI dysfunction, reporting disabling early satiety, bloating, constipation, and/or abdominal pain often to the point of experiencing significant weight loss. Delayed transit time is often seen scintigraphically on motility studies, such as esophageal manometry, gastric emptying study, and/or small bowel transit. Males often report acute to subacute erectile dysfunction and urine retention. Autonomic reflex testing is vital to the diagnosis, and reveals marked orthostatic hypotension with impaired heart rate increment on tilt testing. Impaired late phase II and/or phase IV responses on Valsalva testing signify vascular and cardiac adrenergic impairment while reduced heart rate variation to deep breathing and Valsalva signifies cardiac vagal impairment. Secretomotor findings of global anhidrosis or hypohidrosis on quantitative sudomotor axonal reflex testing (QSART) or thermoregulatory sweat testing (TST) further raise suspicion for AAG. The physical exam finding of non-reactive or sluggish pupils, in the proper clinical context, highly suggests the condition, and can be further quantified using formal pupillometry.[11]

Anatomically, while ganglionopathies often have a widespread and length-independent distribution, the brunt of the symptoms is often due to disproportionate parasympathetic involvement. There are multiple explanations for this, but the fact that the parasympathetic ganglia are very close to end organs plays a significant role.[12] This is in contrast to length-dependent, predominantly small-fiber distal axonal neuropathies, which are often highly involved in certain autonomic neuropathies.

As alluded to earlier, the discovery of the α-3 type gAChR autoantibody, seen in 50% of patients, provides a clear immunologic basis for this condition, with higher titers correlating with greater disease severity.[13,9] Worth noting, however, is that the absence of antibodies does not exclude the diagnosis, and clinical suspicion, autonomic reflex testing, and GI scintigraphic findings should guide evaluation and management. Other antibodies also appear to carry some association with AAG, particularly the N-type calcium channel antibody.[14] Furthermore, although antibody testing may be negative, the presence of inflammatory serologic markers, a personal and family history of autoimmune disease and malignancy, and/or smoking history, should raise suspicion. Left untreated, one-third of patients with AAG improve spontaneously, but even then, recovery is incomplete.

Once a diagnosis of AAG has been formally made, a well-instituted and planned treatment course should be pursued. Although no standard treatment guidelines exist, existing data suggests a therapeutic role for intravenous immunoglobulin (IVIG), pulsed or daily corticosteroids, and plasma exchange.[15,16] While there is no standard dosing regimen, our centers typically use a 12-week treatment trial of either weekly 0.4g/kg IVIG or weekly 1gm intravenous methylprednisolone.[17] Data is limited, however, in terms of optimal dosing and frequency of both therapies. We make sure to document autonomic disease severity at baseline and at completion of the 12-week treatment trial. Plasma exchange also has demonstrated benefit in small series.[18] At the completion of the 12-week treatment trial, assuming a treatment-response, long-term immunosuppressant therapy with such agents as azathioprine,

mycophenolate, or rituximab can be considered, although data regarding such agents is also quite limited.

We use the Composite Autonomic Symptom Scale-31 (COMPASS-31) questionnaire, a validated, abbreviated, and internally consistent measure of autonomic symptom severity that takes 5-10 minutes to administer.[19] The COMPASS-31 questionnaire can distinguish patients with autonomic neuropathy from those without reasonably well. In diabetes, for instance, the COMPASS-31 carries a sensitivity of 75% for cardiac autonomic neuropathy.[20,21] In small fiber polyneuropathy, it is valid and reliable in distinguishing patients with small fiber polyneuropathy from those without.[22] In addition, the COMPASS-31 questionnaire was used to track autonomic symptom evolution and treatment-response in a landmark phase 3 drug study for transthyretin amyloidosis, discussed later in this review.[23]

While AAG is classically classified as a generalized autonomic neuropathy, variants and disease mimickers warrant attention. Seronegative autonomic neuropathy is of particular importance.[24] Relative to seropositive AAG, seronegative AAG is described as having more sensory symptoms, being sympathetic predominant, having less pupillary fatigue, and showing preferential steroid-responsiveness (as opposed to IVIG or plasma exchange). In addition, enteric autoimmune neuropathy is another variant that focally and/or preferentially targets the enteric autonomic system and presents with severe gastroparesis and intestinal pseudo-obstruction.[25] Idiopathic gastroparesis is a frequent referral reason from gastrointestinal to autonomic clinics. A case series from the Mayo Clinic demonstrated an immunotherapeutic response in many

patients, even those who were seronegative. The authors concluded that immunotherapeutic

trials may be considered, when appropriate, as such conditions may represent enteric-restricted

forms of autoimmune autonomic disease. Of note, however, some objective biomarker, such as

scintigraphic evidence of GI slowing or serologic markers, should be present.[25] With regards to

serology, only 10% of patients with idiopathic GI dysmotility and 50% of those with chronic

intestinal pseudo-obstruction, are noted to be gAChR antibody seropositive.[26] Finally, if there

are symptoms or signs of ataxia or large fiber sensory loss, nerve conduction studies and

additional serologic testing can be helpful to evaluate for disease mimickers such as

paraneoplastic neuronopathy, Sjögren's neuronopathy, or acute autonomic and sensory

neuropathy (AASN), a GBS variant,[27] all discussed later.

Paraneoplastic Autonomic Neuropathy

Paraneoplastic autonomic neuropathies represent a similar, albeit distinct etiologic entity.

Unlike idiopathic AAG, a truly paraneoplastic etiology occurs in the setting of malignancy, most

commonly small cell carcinoma of the lung. While ANNA-1 (anti-Hu) is the most well

established antibody, other antibodies should also be considered, namely PCA-2, CRMP-5,

VGKC, and P/Q calcium channel antibodies.[28] Care should be taken to ensure correct antibody-

phenotype correlation. In ANNA-1-associated paraneoplastic autonomic neuropathy, patients

present with severe gastroparesis, and intestinal pseudo-obstruction that often precedes the

diagnosis of malignancy. GI pathology reveals infiltration of the myenteric plexus with plasma

cells and lymphocytes as well as neuronal and axonal degeneration. Lambert-Eaton myasthenic syndrome (LEMS) represents another paraneoplastic etiology when lung cancer is present (found in 60% of LEMS patients).[29] It is an autoimmune-mediated deficit of pre-synaptic neuromuscular transmission where antibodies target P/Q type voltage-gated calcium channels. Autonomic symptoms are present in a majority of patients, are mild, and typically manifest as acute cholinergic neuropathy, with dry eyes, pupillary fatigability, anhidrosis, and constipation. There are no definitive cures for paraneoplastic syndromes and natural history depends on the cancer itself. The appearance of peripheral nervous symptoms in a previously cancer-free patient, however, should raise concern for cancer recurrence. In terms of ancillary studies, nerve conduction studies are particularly important in the setting of antibody-confirmed paraneoplastic autonomic syndromes to assess for concomitant sensory somatic neuronopathy, which is common with anti-Hu and anti-CRMP5 syndromes. In patients with ptosis, proximal weakness, and cholinergic-predominant deficits, repetitive nerve stimulation studies (both low and high frequency) as well as pre- and post-exercise compound muscle action potential testing can be used to confirm the diagnosis of LEMS.

Sjögren's

Sjögren's syndrome is an autoimmune disorder with a lymphocytic inflammatory predilection for exocrine glands and ducts, thus explaining its classic sicca (dry eyes and dry mouth) complex. The autonomic system is frequently perturbed in Sjögren's, and in the proper

clinical context, Sjögren's should be part of the differential.[30,31] Sjögren's involves both the sympathetic and parasympathetic divisions, and often presents with fixed tachycardia and orthostatic hypotension, but can also overlap with postural tachycardia syndrome. Suggestive clues on history include the presence of sicca as well as dry cough, dry nasal passages, acid reflux, and abdominal pain, particularly after fatty meals. The diagnosis is established via serologic testing for anti-Ro (SSA) and anti-La (SSB) antibodies, although minor lip salivary gland biopsy should be pursued if suspected, as antibodies can be falsely negative in many cases.[32] In terms of its natural history, autonomic and somatic sensory deficits not uncommonly precede sicca symptoms in Sjögren's neuropathy patients. The presence of ataxia on exam or sensory neuronopathy on nerve conduction testing should further raise suspicion. Conversely, whenever nerve conduction studies show a length-independent preferential or selective loss of sensory nerve action potentials, Sjögren's should remain at the top of the differential diagnosis unless proven otherwise, even if anti-Ro and anti-La serology is negative, as it is insensitive. A retrospective review conducted at the Mayo Clinic identified various phenotypes associated with Sjögren's, and identified its potential treatment-responsiveness, particularly to IVIG, although no definitive therapies exist.[33]

Guillain Barre Syndrome

Guillain Barre Syndrome (GBS) is an autoimmune-mediated length independent radiculoneuropathy that predominantly targets the somatic system, but also autonomic fibers.

Autonomic disturbances predominantly affect the cardiovascular and gastrointestinal systems and are present in two-thirds of patients.[34,35] Cardiac disturbances manifest in the form of over-reactive or blunted cardiac vagal and cardiac adrenergic responses, with patients often exhibiting sinus tachycardia, dysrhythmias (sometimes potentially fatal arrhythmias), systemic hypertension, bradycardia, and/or blood pressure fluctuation. GI dysmotility and urine retention can occur as well. Demyelination of autonomic fibers in the vagal, glossopharyngeal and preganglionic sympathetic efferents is thought to underlie GBS-induced autonomic injury, with lymphocytic infiltration, neurotoxic cytokine production, and autoantibody targeting thought to impede norepinephrine synthesis and transmission. The diagnosis of GBS is often suggested by the presence of dysautonomia, but other clinical features should alert the clinician and distinguish it from other inflammatory or immune neuropathies, namely chronology of symptoms, respiratory involvement, craniobulbar symptoms, and often an antecedent infection. Whenever autonomic symptoms present rapidly, especially in the setting of associated somatic motor and/or sensory deficits, GBS should always be considered. As discussed earlier, the GBS variant AASN, which is quite prevalent among Asians, should be considered.[27] AASN patients have severe orthostatic hypotension, atonic bladder, gastroparesis, and low plasma norepinephrine levels. Affected patients typically have somatic large and small fiber involvement, with minimal motor impairment. In addition to nerve conduction testing and CSF evaluation, antibody testing (GD1a) can be helpful in diagnosing axonal forms of GBS.[36] Autonomic dysfunction and, in particular, cardiac vagal impairment, portend worse disease

severity and increased mortality in GBS. Dysrhythmias, including potentially fatal arrhythmias, carry the greatest cardiovascular risk of morbidity and mortality. Thus, all GBS patients with autonomic involvement should be monitored with cardiac telemetry while inpatient. In terms of short term prognosis, dysautonomia, along with other clinical factors, such as rapidity of disease progression, bulbar dysfunction, and bilateral facial weakness factors predict a greater likelihood of progression to mechanical ventilation.[37] In terms of outcome, GBS patients with dysautonomia have a 6% mortality as compared to 2% for those without.[38]

Autonomic Neuropathies with a Chronic Onset

<u>Diabetic autonomic neuropathy</u>

Diabetic autonomic neuropathy is underappreciated in diabetics, as symptoms tend to be superseded by more commonly reported complaints from painful somatic neuropathy. Cardiac vagal function is often affected early and symptoms should be screened for as patients may not report them. The exact prevalence of diabetic autonomic neuropathy varies and depends upon diagnostic criteria, patient cohort, and testing modality,[39,40] with estimates ranging from as low as 7% to as high as 90%. A community-based study in Oxford, England revealed a 17% prevalence based on heart rate variability.[41] A separate community-based study showed parasympathetic dysfunction in 65% of patients at 10-year follow-up, with sympathetic dysfunction manifesting

in only 24%.[42] The overall prevalence of autonomic impairment varies by the type of diabetes, with type 1 having a prevalence of 54% and type 2 a prevalence of 73%. Prevalence is impacted by disease duration, age, glycemic control, and metabolic syndrome features, particularly in type 2 diabetes.[43] Clinically, diabetic autonomic neuropathy presents with a myriad of symptoms and affects all major autonomic fibers, although distal small fiber neuropathy, which involves sympathetic sudomotor post-ganglionic secretomotor function, is quite common. In addition, diabetic patients with autonomic deficits may benefit from nerve conduction testing to evaluate for large fiber neuropathy, especially when sensory symptoms are present. On exam, skin changes often occur due to denervation of sweat glands, which results in trophic skin changes and hair loss.

In terms of autonomic symptoms, erectile dysfunction is the most common symptom in males. Cardiovascular, gastrointestinal, and genitourinary symptoms are the most disabling sequelae of diabetic autonomic neuropathy, and are reviewed system-by-system below. Our current understanding of diabetic end-organ damage has shown that the mechanism of nerve injury is unique and separate from retinal or renal injury. In addition, extensive literature now shows that type 1 and type 2 diabetes are largely different disease processes, with type 1 responding favorably to glycemic control, while type 2 responds to treatments aimed at metabolic syndrome, such as lifestyle modification and exercise.[44-46]

The prevalence of cardiac autonomic neuropathy varies from 1-90% for type 1 and 20-73% for type 2 diabetics.[47] It is the most life-threatening form of diabetic autonomic neuropathy,

and independently portends a poor prognosis, with patients having a 27-56% mortality rate at 5-10-year follow-up and an increased risk of sudden cardiac death.[48] A separate study evaluating type 1 diabetic patients with nephropathy found that the presence of abnormal heart rate variation, a marker of cardiac autonomic neuropathy, was associated with an increased risk of fatal and nonfatal cardiovascular disease.[49] A meta-analysis found a strong association between cardiovascular autonomic instability (orthostatic hypotension, resting tachycardia, exercise intolerance and silent myocardial ischemia) and mortality in diabetic patients. All physiologic cardiac functions, such as chronotropy and dronotropy, are impacted. Vagus nerve denervation leads to unopposed sympathetic drive, manifesting as reduced heart rate variability on deep breathing and Valsalva. This then evolves into resting tachycardia and orthostatic hypotension. With continued disease progression, sympathetic cardiac denervation leads to orthostatic hypotension and bradycardia. In light of such findings, silent myocardial infarction (also called cardiac denervation syndrome) in diabetics warrants special mention.[50] A National Registry of Myocardial Infarction survey showed that 32% of diabetic patients with myocardial infarction did not present with any chest pain.[51] Orthostatic hypotension is typically a late manifestation of cardiovascular autonomic neuropathy, present in 6-30% of diabetics (even if asymptomatic), and attributable to impaired sympathetic vasoconstriction of the splanchnic mesenteric and peripheral vascular beds. A prospective Mayo Clinic study found that the most common symptoms on 5 min standing were lightheadedness, weakness, cognitive impairment, and blurred vision.[52] As with all forms of orthostatic hypotension, patients should be asked about exacerbating factors,

such as time of day (worse in morning), meals, and hot showers. Orthostatic hypotension is formally defined as a greater than 20mmHg systolic and/or 10mmHg diastolic drop in pressure within 2 minutes of standing, although this carries lower specificity than the more stringent cutoff of 30mmHg systolic / 15 mmHg diastolic drop, which has been studied in some populations, such as Parkinson patients[53]

Gastrointestinal autonomic neuropathy manifests with dysmotility at nearly any level in the alimentary tract from the esophagus through the rectum, and presents with such symptoms as dysphagia, early satiety, bloating, abdominal pain, constipation, and diarrhea, of which constipation is most common.[54] Beginning in the stomach, gastroparesis is defined as delayed emptying of gastric contents without any evidence of mechanical obstruction, and should be confirmed on gastric emptying studies. It manifests with nausea, vomiting, bloating, and also impaired glycemic control, due to poor food absorption and resultant difficulty in matching insulin requirement. Intestinal neuropathy manifests as diabetic diarrhea, which typically appears as slowed transit time on small bowel studies. Diabetic diarrhea is sudden, explosive, episodic, and disabling, and may also occur with sphincter dysfunction, which furthers fecal incontinence. Constipation results from denervation of the colon and the gastrocolic reflex, and occurs in two-thirds of diabetics. Gastric dysrhythmia refers to a combined picture of constipation, due to bradygastria or slowing of peristaltic movements, and diarrhea, due to tachygastria or enhanced peristaltic movements.

Genitourinary autonomic neuropathy in diabetics presents with such symptoms as neurogenic bladder and erectile dysfunction. Neurogenic bladder, a major problem particularly in type 1 diabetics, manifests with increased post-void residual, overflow incontinence, weak flow, reduced micturition reflex, and atonic bladder. In men, erectile dysfunction occurs in anywhere from one-third to three-fourths of patients with established autonomic neuropathy and may be the first symptom.[55] In erectile dysfunction, parasympathetic fiber denervation leads to impaired smooth muscle relaxation in the corpus callosum. Of note, patients with erectile dysfunction warrant evaluation for cardiovascular disease, as it can be the first sign of cardiovascular injury. In patients with sympathetic injury, retrograde ejaculation may also occur.

Treatment Induced Neuropathy of Diabetes

Treatment-induced diabetic neuropathy is an iatrogenic neuropathy that preferentially targets small and autonomic fibers within weeks of glycemic overcorrection. Although it presents acutely, we include it in this section as a distinct disease category to consider within the broader context of diabetic autonomic neuropathy. It can be precipitated by insulin, hypoglycemic medication, or diet-induced glycemic control, and is generally suspected whenever there is a drop in hemoglobin A1c of at least 2 points over a 3-month period.[56] Although most patient and provider focus is typically directed towards painful small fiber symptoms, autonomic symptoms are quite common. Patients report orthostatic intolerance, bloating, sweat changes, and sexual dysfunction.[57] Autonomic symptom severity correlates with

degree of hemoglobin A1c decline,[58] and a strong correlation exists between the degree of parasympathetic and sympathetic adrenergic impairment and the magnitude of drop of hemoglobin A1c.[56] Natural history is altered by glycemic control, as autonomic findings on formal testing show improvement in patients with stable glycemic control, with sympathetic adrenergic and parasympathetic impairment normalizing after 8-year follow up in one study.[58] In patients with unstable glycemic control, autonomic testing shows continued worsening. A 2010 study shed some additional light on differences between type 1 and type 2 diabetics. Type 1 diabetics reported more frequent and severe autonomic symptoms as compared to type 2 patients, typically with respect to orthostatic intolerance and GI dysfunction.[59] In addition, natural history varies by type. On 18-month follow up, type 1 patients reported improvement in autonomic symptoms, while type 2 patients did not.

Amyloidosis

Amyloidosis involves the excessive generation and deposition of insoluble fibrillary proteins in β-pleated sheets in various organ systems, and has acquired and hereditary forms. While autonomic symptoms overlap and will be discussed together, we discuss each condition's pathophysiology and treatment separately in this section.

Autonomic neuropathy symptoms in amyloid are widespread.[60] Symptoms tend to be more severe and rapidly progressive than in other chronic conditions, but not typically as abrupt as AAG, for example. Patients can describe widespread anhidrosis with compensatory

hyperhidrosis, significant GI dysmotility (confirmed on scintigraphy), orthostatic intolerance (manifest on autonomic testing), as well as erectile dysfunction in males. Orthostatic hypotension from vascular and cardiac adrenergic impairment often leads to syncope or near syncope. As with AAG, amyloid can produce pan-dysautonomia on autonomic reflex testing, with marked and, oftentimes global, reduction in sudomotor sweat output and significantly blunted cardiac vagal, as well as cardiac and vascular adrenergic function. In addition to autonomic symptoms, other clinical and electrodiagnostic clues are often present. The presence of cardiomyopathy, nephrotic syndrome, axonal peripheral neuropathy, weight loss, macroglossia, hepatomegaly, and/or significant GI dysmotility should raise concern for amyloidosis. Scalloping of the pupillary margin is sometimes noted on exam. Nerve conduction testing typically reveals a length dependent sensorimotor axonal peripheral neuropathy, often with superimposed carpal tunnel syndrome. Additional diagnostic tests include fat pad aspiration, rectal or gingival mucosal biopsy, or nerve biopsy evaluation with Congo red staining. Nerve histopathology reveals deposition of amyloid protein as seen on Congo red staining, predominantly involving small myelinated or unmyelinated fibers and the autonomic ganglia. When the hereditary form is suspected, genetic testing should be pursued prior to any biopsy evaluation.

A. Amyloidosis: Amyloid light chain subtype

Amyloid light chain (AL) amyloidosis is the most common form of amyloid in the United States, and generally affects patients ages 50-80, with a 2:1 male to female predilection. It involves the mis-folding of the light chain antibody, either lambda or kappa, and its deposition in tissue. Bone marrow or tissue biopsy is usually required to positively secure the diagnosis, although other tests can be highly suggestive, including immunofixation electrophoresis, free light chains, 24 h urine immunofixation, alkaline phosphatase, troponin, and N-terminal brain natriuretic peptide (NT-proBNP). In addition, echocardiographic findings can include ventricular wall thickening, significant diastolic impairment, and a restrictive filling pattern. MR imaging can reveal diffuse and irregular hyperenhancement of myocardium that is usually circumferential and subendocardial. The peripheral neuropathy tends to progress with or without treatment, although mortality is typically due to other medical complications.[61] For AL amyloid, first-line therapy consists of cyclophosphamide, bortezomib and dexamethasone (CyBorD therapy).[62] Emerging therapies also show promise, including the newly FDA approved daratumumab, a CD-38 directed monoclonal antibody.[63] In selected patients, stem cell transplant can also prolong survival.[64-66]

B. Amyloidosis: Transthyretin familial amyloid polyneuropathy subtype

Within the broad family of familial amyloid polyneuropathy (FAP), which refers to all hereditary forms of amyloidosis, we focus our discussion on TTR-associated FAP patients. 75% of TTR-FAP patients have autonomic neuropathy.[67] In TTR amyloidosis, the liver produces

mutated TTR protein that causes unstable tetramers, which subsequently dissociate into monomers, and which then form oligomers and fibrils. The fibrils subsequently deposit in multiple end organs, including autonomic and somatic sensory nerves as well as heart, kidney, gastrointestinal tract, vitreous fluid, spinal canal, and carpal tunnel. A family history of unexplained peripheral neuropathy or recurrent carpal tunnel syndrome should raise concern for TTR amyloidosis. TTR amyloidosis itself is associated with numerous variants, the most common of which is the Val30Met mutation, prevalent in Portugal, Brazil, Sweden, and Japan.[68] Amongst African Americans, the Val122Ile mutations is the most common.[69] TTR is further subdivided into early onset (<50y) and late onset (>50y), with early onset having a significant degree of autonomic impairment, in contradistinction to late onset. In addition to tissue biopsy and other serum and urine based tests discussed previously, genetic testing for TTR is now commercially available. Technetium-99 pyrophosphate cardiac imaging is a useful confirmatory test in cases of suspected TTR cardiomyopathy, often precluding the need for endomyocardial tissue biopsy.[70] Autonomic symptoms can be associated with high morbidity, with arrhythmias contributing to sudden death in some. The severity of cardiac autonomic impairment, however, does not always correlate with the severity of somatic neuropathy in TTR amyloid, and both fiber types (somatic and autonomic) should be given full independent consideration in any patient.[71]

For TTR amyloidosis, the emergence of two new FDA-approved therapies holds great promise. Patisiran, an RNA interference therapy, is administered intravenously once every 3

weeks, and has been shown to halt and even reverse neuropathy.[72] It also lessens autonomic

impairment in TTR amyloid patients as compared to untreated patients. Inotersen, an antisense

oligonucleotide administered intravenously once weekly, is another recently FDA-approved

therapy that inhibits hepatic production of transthyretin by binding to TTR mRNA and targeting

it for degradation via RNAase. It improves neurologic disability scores as well as quality of life.

Both drugs work by targeting the 3′ untranslated region of transthyretin mRNA. Other therapies

available include tafamidis[73] as well as diflunisal. Finally, liver transplant remains a

consideration for TTR, particularly those with the Val30Met mutation (74% post-transplant

survival).[74]

Hereditary Sensory Autonomic Neuropathies

Hereditary sensory autonomic neuropathies (HSANs) are a heterogeneous group of

familial disorders that preferentially target autonomic and small fibers, traditionally divided into

5 subtypes, with nuanced phenotype-genotype correlations (**Table 1**).[75] In this section, only

HSAN-I is discussed in detail as it is the only subtype that presents in adulthood. In general, any

unexplained dysregulation of sweating, lacrimation, breathing pattern, pain sensitivity, or

temperature control, especially in children, should prompt consideration for genetic testing for

any HSAN subtype. HSAN I is autosomal dominant and associated with a pathogenic mutation

in the *SPTLC1* gene on chromosome 9q22.1-q22.3. Clinically, patients develop pain and

temperature loss early, often in the second decade of life, and may develop position and vibration

sensory loss later in disease course.[76] Sweating disturbances are the most commonly-observed autonomic impairment.[77] Nerve conduction testing typically shows a sensory axonal peripheral neuropathy, with sural nerve biopsies showing concordant axonal loss. Management of HSAN I, as well as most other HSAN subtypes, follows similar guidelines as for diabetic foot care, including proper ulcer care to prevent infection as well as counseling to avoid ulcer development.[77]

<u>Postural orthostatic tachycardia syndrome</u>

Postural tachycardia syndrome (POTS) is a disorder that is not classically considered an autonomic neuropathy, but warrants attention in this context. It is defined by a sustained heart rate increase from baseline of 30 beats per minute or more in the absence of orthostatic hypotension on tilt table testing.[78] Clinically, it is characterized by suggestive patient profile, clinical complaints, and the absence of more widespread autonomic neuropathy. It is most commonly seen in the 15-50-year age range and has a 4:1 female to male preponderance. Symptoms are widespread, but tend to revolve around fatigue, palpitations, cognitive slowing, orthostatic intolerance, exercise intolerance, diffuse body pain, GI complaints, among a host of other symptoms. Associations exist with preceding trauma, viral illness, or pregnancy, as well as the presence of such concomitant conditions as anxiety, Chiari malformation, mitral valve prolapse, mast cell activation syndrome, and Ehlers Danlos syndrome. The prognosis is generally favorable for most POTS patients, especially with treatment, although a subset of

patients, especially those with a systemic exertion intolerance disorder (SEID) phenotype, may not respond or continue to decline.

Other acute and chronic causes of autonomic neuropathy are summarized in **Table 2**.

A proposed approach to the evaluation and treatment of autonomic neuropathies

Evaluation

The proper evaluation of autonomic neuropathy rests upon a complete history and examination, followed by formal autonomic reflex screening and appropriate ancillary testing to corroborate such findings (**Figure 1**). A thorough autonomic review of systems should be conducted, screening for such symptoms as dry eyes, dry mouth, orthostatic intolerance or lightheadedness, exertional intolerance, dyspnea, chest pressure, fatigue, abdominal pressure, bloating, constipation, diarrhea, early satiety, urinary urgency, urinary frequency, erectile dysfunction, decreased libido, anhidrosis, heat or cold intolerance, as well as acral redness or swelling or numbness, to name some of the more common symptoms. Personal or family history of autoimmune disease (particularly connective tissue disease), cancer, or genetic disorder should be queried. Chemotherapy or other toxic drug exposure, travel history, and alcohol consumption should also be screened for. Medications and supplements that could contribute to autonomic symptoms should be reviewed. Disease mimickers should also be excluded, such as pheochromocytoma, adrenal insufficiency, thyroid disorders, anemia, or structural cardiac

disease. Depending on symptomatic presentation, testing should include serum and urine catecholamines, serum cortisol, CBC, ECG, echocardiogram, and Holter monitor evaluation.

In patients with autonomic neuropathy, the examination should note the presence of pupillary non-responsiveness, acral sensory pinprick and vibratory loss, proprioceptive or ataxic proprioceptive sensory loss, and areflexia. One should evaluate for skin discoloration, change in skin temperature, acral swelling, trophic changes, and joint hypermobility.

Temporal disease onset is also particularly useful in the evaluation of etiology. Acute or subacute autonomic symptom onset should prompt consideration for AAG, paraneoplastic peripheral autonomic neuropathy, GBS, botulism, toxins or infections. The presence of tonic or sluggishly reactive pupils raises concern for AAG, and formal pupillometer testing can be very helpful. In the setting of severe GI dysmotility, urine retention, anhidrosis, and/or erectile dysfunction, AAG should be further entertained, even in the absence of gAChR antibody. GI scintigraphic studies should be pursued if AAG is suspected. TST is also helpful in AAG both in its diagnosis and in monitoring its treatment response. Sicca symptoms should prompt consideration of Sjögren's, which should be screened for with anti-Ro and anti-La antibodies, and minor lip salivary gland biopsy if suspicion is high.

Should the autonomic neuropathy be chronic in onset, diabetic autonomic neuropathy must always be evaluated for using fasting and 2 h glucose tolerance testing, although TIND presents acutely. In addition, immunofixation electrophoresis should be pursued to evaluate for AL amyloid. Free light chain, urine 24h protein, TTR genetic testing, tissue biopsy, and/or PYP

cardiac scintigraphic scanning can be added as needed. If suspected, celiac disease testing can be pursued through IgA or IgG gliadin and tissue transglutaminase testing, and if need be, endoscopic small intestinal biopsy. Genetic testing for HSAN can be considered, especially in the setting of a suggestive history and/or pes cavus. For all such chronic autonomic neuropathies, intraepidermal nerve fiber density evaluation through skin biopsies (not part of the autonomic reflex screen) are very helpful. POTS should also be considered in the evaluation of autonomic neuropathies. Acral redness and blanching erythema, especially upon standing, should raise concern for vascular insufficiency or venous pooling, especially in the presence of associated joint hypermobility. Supine and standing catecholamines can be helpful to evaluate for hyperadrenergic POTS.

Symptomatic Treatment

Disease-modifying therapies are discussed in their respective sections. In this section, we discuss the general therapeutic approach to autonomic neuropathies, including symptomatic therapies. Treatment for autonomic neuropathies rests on three pillars, namely (1) disease modifying therapy, when possible, (2) dietary/behavioral based therapy, and (3) symptomatic pharmacologic therapy. Aggravating factors should be addressed, including the avoidance of certain medications (beta-blockers, phosphodiesterase-5 inhibitors, alpha-blockers, diuretics, calcium channel blockers, and tricyclic antidepressants) as well as the treatment of anemia, thyroid disorders, or adrenal insufficiency, as seen appropriate. With regard to disease

modifying therapy for such conditions as AAG, AL amyloid, and TTR amyloid, it is important to assess baseline and post-treatment disease activity using such validated outcome measures as the COMPASS-31. Autonomic reflex testing can also be performed at baseline and post-treatment for objective surveillance.

For dietary/behavioral and symptomatic pharmacologic therapy, these are individualized per autonomic system involved, but largely center on the gastrointestinal, genitourinary, and cardiovascular systems. For treatment of orthostatic hypotension, for example, various non-pharmacologic and pharmacologic therapies exist. Non-pharmacologic treatment includes volume expansion via increased salt intake, increased fluid intake, compression of legs (thigh high, 20-30mmHg) and abdomen, raising the head of the bed 4-6", and graded exercise tolerance training. Multiple medications exist and medication choice should be guided by adverse effect profile. Droxidopa is a recently FDA-approved therapy for the treatment of orthostatic hypotension. It seems to have the greatest impact on patients with supine norepinephrine < 200 pg/mL. Concomitant use with norepinephrine reuptake inhibitors or adrenergic agonists should be done cautiously. Fludrocortisone is an excellent once-daily choice for orthostatic hypotension, but can worsen supine hypertension. One should monitor blood pressure, especially in those with essential or supine hypertension, in addition to serum potassium and renal function. Midodrine is also a reasonable alternative and is dosed thrice daily. Choice of treatment is guided by disease state, medication adverse event profile, and cost. POTS alone has an evolving spectrum of medicinal interventions that are now routinely prescribed.

For symptomatic treatment of GI dysmotility, bladder dysfunction, sicca, and heat intolerance, treatments are to be guided by complaints, adverse event profile, and patient preference.[1] For constipation, for example, increased dietary fiber, pelvic floor training, stool softeners, laxatives, and pro-motility agents are helpful, while for bowel incontinence, pelvic floor training, sanitary devices, and regular bowel habits are helpful. For bladder retention, self-catheterization and neural stimulation may be indicated, while for overflow incontinence, pelvic floor strengthening and antimuscarinic and/or beta-3-receptor agonists may be considered. For patients with significant dryness of eyes, pilocarpine drops, artificial tears, and lubricating ointments are helpful, while for dryness of mouth, numerous sialogogues exist.[79] Offending drugs should be eliminated. For heat intolerance and anhidrosis or hypohidrosis, offending agents should be eliminated prior to initiation of potential drug therapy.

Conclusion

Autonomic neuropathies are complex and debilitating disorders that warrant a nuanced and systematic approach in their evaluation and treatment, not unlike that employed in the evaluation of somatic neuropathies. After classifying disease by temporal onset and clinical presentation, autonomic reflex testing should be performed expeditiously to permit prompt and appropriate treatment, and should complement a careful history, exam, serologic testing, electrodiagnostic testing, scintigraphic testing, imaging and tissue biopsy, where appropriate. The emergence of disease modifying therapies makes this even more urgent, as the timely application of such therapies can potentially improve patient function and quality of life.

Abbreviations

AAG, autoimmune autonomic ganglionopathy; GI, gastrointestinal; gAChR, ganglionic

acetylcholine receptor antibody; QSART, quantitative sudomotor axonal reflex testing; TST,

thermoregulatory sweat testing; IVIG, intravenous immunoglobulin; COMPASS-31, Composite

Autonomic Symptom Scale-31; GBS, Guillain Barre Syndrome; AASN, acute autonomic and

sensory neuropathy; AL; TTR, transthyretin; HSAN, hereditary sensory autonomic neuropathy;

POTS, postural tachycardia syndrome.

References

1.   Iodice V, Sandroni P. Autonomic neuropathies. Continuum (Minneap Minn) 2014;20(5 Peripheral Nervous System Disorders):1373-1397.

2.   Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve 2003;27(6):646-661.

3.   Freeman R. Autonomic Peripheral Neuropathy. Continuum (Minneap Minn) 2020;26(1):58-71.

4.   Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol 2013;9(1):1-8.

5.   Suarez GA, Fealey RD, Camilleri M, Low PA. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. Neurology 1994;44(9):1675-1682.

6.   Vernino S. Autoimmune Autonomic Disorders. Continuum (Minneap Minn) 2020;26(1):44-57.

7.   McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009;66(6):735-741.

8.   Li Y, Jammoul A, Mente K, Li J, Shields RW, Vernino S, Rae-Grant A. Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. Muscle Nerve 2015;52(3):386-391.

9.   Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343(12):847-855.

10.   Koike H, Koyano S, Morozumi S, Kawagashira Y, Iijima M, Katsuno M, Hattori N, Vernino S, Sobue G. Slowly progressive autonomic neuropathy with antiganglionic acetylcholine receptor antibody. J Neurol Neurosurg Psychiatry 2010;81(5):586-587.

11.   Muppidi S, Adams-Huet B, Tajzoy E, Scribner M, Blazek P, Spaeth EB, Frohman E, Davis S, Vernino S. Dynamic pupillometry as an autonomic testing tool. Clin Auton Res 2013;23(6):297-303.

12.   Benarroch EE. Physiology and Pathophysiology of the Autonomic Nervous System. Continuum (Minneap Minn) 2020;26(1):12-24.

13.   Klein CM, Vernino S, Lennon VA, Sandroni P, Fealey RD, Benrud-Larson L, Sletten D, Low PA. The spectrum of autoimmune autonomic neuropathies. Ann Neurol 2003;53(6):752-758.

14.   Kimpinski K, Iodice V, Vernino S, Sandroni P, Low PA. Association of N-type calcium channel autoimmunity in patients with autoimmune autonomic ganglionopathy. Auton Neurosci 2009;150(1-2):136-139.

15.   Gibbons CH, Vernino SA, Freeman R. Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol 2008;65(2):213-217.

16.   Iodice V, Kimpinski K, Vernino S, Sandroni P, Fealey RD, Low PA. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology 2009;72(23):2002-2008.

17.   Mckeon A, Benarroch EE. Autoimmune autonomic disorders. Handb Clin Neurol 2016;133:405-416.

18.   Schroeder C, Vernino S, Birkenfeld AL, Tank J, Heusser K, Lipp A, Benter T, Lindschau C, Kettritz R, Luft FC, Jordan J. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med 2005;353(15):1585-1590.

19.   Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012;87(12):1196-1201.

20.   Greco C, Di Gennaro F, D'Amato C, Morganti R, Corradini D, Sun A, Longo S, Lauro D, Pierangeli G, Cortelli P, Spallone V. Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes. Diabet Med 2017;34(6):834-838.

21.   D'Amato C, Greco C, Lombardo G, Frattina V, Campo M, Cefalo CMA, Izzo V, Lauro D, Spallone V. The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy. J Peripher Nerv Syst 2020;25(1):44-53.

22.   Treister R, O'Neil K, Downs HM, Oaklander AL. Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy. Eur J Neurol 2015;22(7):1124-1130.

23.   Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid 2020:1-10.

24.   Golden EP, Bryarly MA, Vernino S. Seronegative autoimmune autonomic neuropathy: a distinct clinical entity. Clin Auton Res 2018;28(1):115-123.

25.   Flanagan EP, Saito YA, Lennon VA, McKeon A, Fealey RD, Szarka LA, Murray JA, Foxx-Orenstein AE, Fox JC, Pittock SJ. Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility. Neurogastroenterol Motil 2014;26(9):1285-1297.

26.   Mukaino A, Minami H, Isomoto H, Hamamoto H, Ihara E, Maeda Y, Higuchi O, Okanishi T, Kokudo Y, Deguchi K, Sasaki F, Ueki T, Murata KY, Yoshida T, Kinjo M, Ogawa Y, Ido A, Matsuo H, Nakao K, Nakane S. Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. J Gastroenterol 2018;53(12):1227-1240.

27.   Koike H, Atsuta N, Adachi H, Iijima M, Katsuno M, Yasuda T, Fukada Y, Yasui K, Nakashima K, Horiuchi M, Shiomi K, Fukui K, Takashima S, Morita Y, Kuniyoshi K, Hasegawa

Y, Toribe Y, Kajiura M, Takeshita S, Mukai E, Sobue G. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010;133(10):2881-2896.

28.   Golden EP, Vernino S. Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clin Auton Res 2019;29(3):277-288.

29.   Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10(12):1098-1107.

30.   Brunetta E, Shiffer D, Mandelli P, Achenza S, Folci M, Zumbo A, Minonzio M, Cairo B, Jacob G, Boccassini L, Puttini PS, Porta A, Furlan R. Autonomic Abnormalities in Patients With Primary Sjogren's Syndrome - Preliminary Results. Front Physiol 2019;10:1104.

31.   Koh JH, Kwok SK, Lee J, Park SH. Autonomic dysfunction in primary Sjogren's syndrome: a prospective cohort analysis of 154 Korean patients. Korean J Intern Med 2017;32(1):165-173.

32.   Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am 2016;42(3):419-434.

33.   Goodman BP. Immunoresponsive Autonomic Neuropathy in Sjögren Syndrome-Case Series and Literature Review. Am J Ther 2019;26(1):e66-e71.

34.   Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: an update. Clin Auton Res 2019;29(3):289-299.

35.   Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994;17(10):1145-1155.

36.   Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, Griffin JW, McKhann GM. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45(2):168-173.

37.   Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001;58(6):893-898.

38.   Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocrit Care 2020;32(1):113-120.

39.   Vinik AI, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol 2013;117:279-294.

40.   Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992;6(1):49-57.

41.   Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med 1989;6(1):20-24.

42.   Töyry JP, Niskanen LK, Mäntysaari MJ, Länsimies EA, Uusitupa MI. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 1996;45(3):308-315.

43.   Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac

Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative

Review. Diabetes Ther 2019;10(6):1995-2021.

44.   Callaghan BC, Hur J, Feldman EL. Diabetic neuropathy: one disease or two? Curr Opin

Neurol 2012;25(5):536-541.

45.   Callaghan BC, Gao L, Li Y, Zhou X, Reynolds E, Banerjee M, Pop-Busui R, Feldman

EL, Ji L. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clin

Transl Neurol 2018;5(4):397-405.

46.   Callaghan BC, Xia R, Banerjee M, de Rekeneire N, Harris TB, Newman AB, Satterfield

S, Schwartz AV, Vinik AI, Feldman EL, Strotmeyer ES, Study HA. Metabolic Syndrome

Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic

Status. Diabetes Care 2016;39(5):801-807.

47.   Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients

with diabetes mellitus. World J Diabetes 2014;5(1):17-39.

48.   Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular

autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care

2003;26(6):1895-1901.

49.   Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic

neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with

diabetic nephropathy. Diabetes Care 2006;29(2):334-339.

50.   Airaksinen KE. Silent coronary artery disease in diabetes--a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001;44(2):259-266.

51.   Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT, Ornato JP, Barron HV, Kiefe CI. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000;283(24):3223-3229.

52.   Low PA, Opfer-Gehrking TL, McPhee BR, Fealey RD, Benarroch EE, Willner CL, Suarez GA, Proper CJ, Felten JA, Huck CA. Prospective evaluation of clinical characteristics of orthostatic hypotension. Mayo Clin Proc 1995;70(7):617-622.

53.   Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, Kaufmann H. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 2015;30(5):639-645.

54.   Maleki D, Locke GR, Camilleri M, Zinsmeister AR, Yawn BP, Leibson C, Melton LJ. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160(18):2808-2816.

55.   Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25(8):1458-1463.

56.   Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015;138(Pt 1):43-52.

57.   Gibbons CH. Treatment-Induced Neuropathy of Diabetes. Curr Diab Rep 2017;17(12):127.

58.   Gibbons CH. Treatment induced neuropathy of diabetes-Long term implications in type 1 diabetes. J Diabetes Complications 2017;31(4):715-720.

59.   Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010;67(4):534-541.

60.   Wang AK, Fealey RD, Gehrking TL, Low PA. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc 2008;83(11):1226-1230.

61.   Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 1979;6(1):1-7.

62.   Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119(19):4391-4394.

63.   Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 2017;130(7):900-902.

64.   Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ, Gertz MA. Stem Cell

Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol 2018;36(13):1323-1329.

65.   Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biol Blood Marrow Transplant 2019;25(8):1520-1525.

66.   Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, Kumar SK, Gertz MA. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol 2019.

67.   Pearson KT, Vota S. Amyloidosis and its management: Amyloid neuropathies. Curr Probl Cancer 2016;40(5-6):198-208.

68.   Rudolph T, Kurz MW, Farbu E. Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history. Clin Med Res 2008;6(2):80-82.

69.   Shah KB, Mankad AK, Castano A, Akinboboye OO, Duncan PB, Fergus IV, Maurer MS. Transthyretin Cardiac Amyloidosis in Black Americans. Circ Heart Fail 2016;9(6):e002558.

70.   Bokhari S, Shahzad R, Castaño A, Maurer MS. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol 2014;21(1):175-184.

71.   Kapoor M, Rossor AM, Laura M, Reilly MM. Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. J Neuromuscul Dis 2019;6(2):189-199.

72.   Conceição I. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. Clin Auton Res 2019;29(Suppl 1):11-17.

73.   Cruz MW. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clin Auton Res 2019;29(Suppl 1):19-24.

74.   Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31.

75.   Rotthier A, Baets J, Timmerman V, Janssens K. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neurol 2012;8(2):73-85.

76.   Houlden H, King R, Blake J, Groves M, Love S, Woodward C, Hammans S, Nicoll J, Lennox G, O'Donovan DG, Gabriel C, Thomas PK, Reilly MM. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 2006;129(Pt 2):411-425.

77.   Auer-Grumbach M. Hereditary sensory neuropathy type I. Orphanet J Rare Dis 2008;3:7.

78.   Goodman BP. Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci 2018;215:12-19.

79.   Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. Nat Rev Rheumatol 2016;12(8):456-471.

LEGEND for FIGURE 1. Diagnostic approach to autonomic neuropathies.

CV, cardiovascular; GI, gastrointestinal; GU, genitourinary; ED, erectile dysfunction; ARS, autonomic reflex screen; ECG, electrocardiogram; TST, thermoregulatory sweat test; MR, magnetic resonance; PNS, peripheral nervous system; CNS, central nervous system; NMDA, Anti-N-methyl D-aspartate (NMDA) encephalitis; OH, orthostatic hypotension; NCS, nerve conduction studies; AAG, autoimmune autonomic ganglionopathy; LEMS, Lambert Eaton Myasthenic Syndrome; ANNA-1, anti-neuronal nuclear antibody type 1; CRMP-5, Collapsin response mediator protein 5; ANA, antinuclear antigen; ENA, extractable nuclear antigen; GBS, Guillain Barre Syndrome; AASN, acute autonomic and sensory neuropathy; TIND, treatment-induced neuropathy of diabetes; AL, acquired light chain; TTR, transthyretin; HSAN, Hereditary sensory autonomic neuropathy; TTG, tissue transglutaminase; IENFD, intraepidermal nerve fiber density; POTS, postural tachycardia syndrome; OH, orthostatic hypotension; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Recognize the presence of autonomic dysfunction:
-CV-hypotension, tachycardia
-GI-bloating, early satiety, constipation
-GU-neurogenic bladder, ED
-Secretomotor-anhidrosis, sicca
-Pupillomotor-blurred vision

Exclude secondary causes:
(as appropriate)
-Adrenal insufficiency
-Pheochromocytoma
-Medications
-Anemia
-Cardiac structural or rhythmic disease
-Thyroid disorders

Objective testing:
(guided by clinical evaluation):
-Autonomic reflex screen (ARS)
-ECG, Holter, echocardiogram
-Lab testing (guided by symptoms)
-Orthostatic catecholamines*
-Skin biopsy (IENFD)*
-Nerve conduction testing*
-Thermoregulatory sweat test (TST)*
-GI scintigraphy studies*
-Cardiac nuclear imaging*
-MR brain imaging*
-Tissue biopsy*

Exclude CNS processes:
(as appropriate)
-α-synucleinopathies
Parkinson disease
Multi-system atrophy
Pure autonomic failure
(PNS-predominant but may progress to other CNS-predominant α-synucleinopathies)
-Multiple sclerosis
-Encephalitides (NMDA)
-Traumatic brain or spinal cord injury

Acute or Subacute ← Once PNS autonomic neuropathy established, define the temporal onset → **Chronic**

Diabetes mellitus (chronic) — Distal painful small (or large) fiber neuropathy, retinopathy, nephropathy, foot ulcers, cardiac disease, erectile dysfunction.

TIND (acute) — If > 2-point drop in HbA1c in 3 months or less with pain

Triad of OH, anhidrosis, GI dysmotility; Pupillary non-reactivity; + ganglionic AChR antibody (50% only) or N-type calcium channel antibodies; delayed emptying on GI nuclear studies; smoking history; concomitant autoimmune clinical and serologic profile; associated sensory neuronopathy (NCS)
AAG or variants

Amyloid
AL
TTR
Monoclonal gammopathy (can be light-chain only); cardiomyopathy, vitreous opacities, macroglossia; advancing sensorimotor neuropathy on NCS; carpal tunnel syndrome; + sural nerve (or other tissue) biopsy for amyloid deposit; +Technetium-99 cardiac scan; +genetic testing for TTR

Malignancy; + ANNA, + CRMP-5, + P/Q Ca channel antibody (LEMS); associated sensory neuronopathy (NCS)
Paraneoplastic

Ascending weakness; areflexia; CSF albuminocytologic dissociation; suggestive NCS; + GD1 antibody
GBS or variants (AASN)

HSAN — + Family history, congenital onset, excess foot ulcers, bony deformities, alacrima, anhidrosis, temperature dysregulation, pain-insensitivity. Testing for *SPTLC1, HSN2, ELP1, NTRK1*.

Sicca; + anti-Ro, anti-La, ANA; ENA; small fiber or large fiber sensory neuropathy or sensory ganglionopathy.
Sjögren & other autoimmune connective tissue

celiac — Gluten enteropathy; IgA or TTG positive

SFN — Anhidrosis, +IENFD, acral symptoms

Preceding infection
(as suggested by associated symptoms):
Botulism, Leprosy, Chagas, Hepatitis C (chronic)

POTS — +30bpm increment on tilt without underlying cardiac disease or OH; joint laxity (Ehlers Danlos Syndrome); young age, female gender, preceding viral illness or trauma

Preceding drug exposure:
Cisplatinum, Vincristine, Amiodarone, Alcohol (chronic), Others

Orthostatic Hypotension — 20mmHg SBP or 10mmHg DBP drop. No other underlying cause

MUS_27048_Figure 1_diagnostic algorithm_enlarged.jpg

WOLTERS KLUWER HEALTH, INC. LICENSE
TERMS AND CONDITIONS

Mar 12, 2020

This Agreement between Harmanpreet Tiwana ("You") and Wolters Kluwer Health, Inc. ("Wolters Kluwer Health, Inc.") consists of your license details and the terms and conditions provided by Wolters Kluwer Health, Inc. and Copyright Clearance Center.

All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.

License Number	4786641134383
License date	Mar 12, 2020
Licensed Content Publisher	Wolters Kluwer Health, Inc.
Licensed Content Publication	Continuum
Licensed Content Title	Autonomic Neuropathies
Licensed Content Author	Valeria Iodice and Paola Sandroni
Licensed Content Date	Oct 1, 2014
Licensed Content Volume	20
Licensed Content Issue	5
Type of Use	Journal/Magazine

Requestor type	STM Signatory Publisher
STM publisher name	Wiley
Format	Print and electronic
Portion	Figures/tables/illustrations
Number of figures/tables/illustrations	2
Author of this Wolters Kluwer article	Yes
Will you be translating?	No
Will your content be published as Open Access?	No
Intend to modify/adapt the content	Yes
Title of new article	Autonomic neuropathies
Lead author	Divpreet Kaur, Harmanpreet Tiwana, Amro Stino, Paola Sandroni
Title of targeted journal	Muscle and Nerve
Publisher	Wiley
Expected publication date	May 2020
Portions	Table 12-9 and 12-11
Additional Information	Dr. Paola Sandroni will be the senior author. She has asked me to request your permission for copyright.

Requestor Location	Harmanpreet Tiwana One Medical Center Drive LEBANON, NH 03756 United States Attn: Harmanpreet Tiwana
Publisher Tax ID	13-2932696
Billing Type	Credit Card
Credit card info	American Express ending in 1002
Credit card expiration	04/2023
Total	198.90 USD

Terms and Conditions

4. **Indemnity:** You hereby indemnify and hold harmless Wolters Kluwer Health, Inc. and its respective officers, directors, employees and agents, from and against any and all claims, costs, proceeding or demands arising out of your unauthorized use of the Licensed Material

5. **Geographical Scope:** Permission granted is non-exclusive and is valid throughout the world in the English language and the languages specified in the license.

6. **Copy of Content:** Wolters Kluwer Health, Inc. cannot supply the requestor with the original artwork, high-resolution images, electronic files or a clean copy of content.

7. **Validity:** Permission is valid if the borrowed material is original to a Wolters Kluwer Health, Inc. imprint (J.B Lippincott, Lippincott-Raven Publishers, Williams & Wilkins, Lea & Febiger, Harwal, Rapid Science, Little Brown & Company, Harper & Row Medical, American Journal of Nursing Co, and Urban & Schwarzenberg - English Language, Raven Press, Paul Hoeber, Springhouse, Ovid), and the Anatomical Chart Company

8. **Third Party Material:** This permission does not apply to content that is credited to publications other than Wolters Kluwer Health, Inc. or its Societies. For images credited to non-Wolters Kluwer Health, Inc. books or journals, you must obtain permission from the source referenced in the figure or table legend or credit line before making any use of the image(s), table(s) or other content.

9. **Adaptations:** Adaptations are protected by copyright. For images that have been adapted, permission must be sought from the rightsholder of the original material and the rightsholder of the adapted material.

10. **Modifications:** Wolters Kluwer Health, Inc. material is not permitted to be modified or adapted without written approval from Wolters Kluwer Health, Inc. with the exception of text size or color. The adaptation should be credited as follows: Adapted with permission from Wolters Kluwer Health, Inc.: [the author(s), title of book, edition, copyright holder, year of publication] or [the author(s), titles of article, title of journal, volume number, issue number, inclusive pages and website URL to the journal page].

11. **Full Text Articles:** Republication of full articles in English is prohibited.

12. **Branding and Marketing:** No drug name, trade name, drug logo, or trade logo can be included on the same page as material borrowed from *Diseases of the Colon & Rectum, Plastic Reconstructive Surgery, Obstetrics & Gynecology (The Green Journal), Critical Care Medicine, Pediatric Critical Care Medicine, the American Heart Association publications and the American Academy of Neurology publications.*

13. **Open Access:** Unless you are publishing content under the same Creative Commons license, the following statement must be added when reprinting material in Open Access journals: "The Creative Commons license does not apply to this content. Use of the material in any format is prohibited without written permission from the publisher, Wolters Kluwer Health, Inc. Please contact permissions@lww.com for further information."

14. **Translations:** The following disclaimer must appear on all translated copies: Wolters Kluwer Health, Inc. and its Societies take no responsibility for the accuracy of the translation from the published English original and are not liable for any errors which may occur.

15. **Published Ahead of Print (PAP):** Articles in the PAP stage of publication can be cited using the online publication date and the unique DOI number.
    i. Disclaimer: Articles appearing in the PAP section have been peer-reviewed and accepted for publication in the relevant journal and posted online before print

publication. Articles appearing as PAP may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Any final changes in manuscripts will be made at the time of print publication and will be reflected in the final electronic version of the issue. Accordingly, Wolters Kluwer Health, Inc., the editors, authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in the articles in this section.

16. **Termination of Contract:** Wolters Kluwer Health, Inc. must be notified within 90 days of the original license date if you opt not to use the requested material.

17. **Waived Permission Fee:** Permission fees that have been waived are not subject to future waivers, including similar requests or renewing a license.

18. **Contingent on payment:** You may exercise these rights licensed immediately upon issuance of the license, however until full payment is received either by the publisher or our authorized vendor, this license is not valid. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of Wolters Kluwer Health, Inc.'s other billing and payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

19. **STM Signatories Only:** Any permission granted for a particular edition will apply to subsequent editions and for editions in other languages, provided such editions are for the work as a whole in situ and do not involve the separate exploitation of the permitted illustrations or excerpts. Please view: STM Permissions Guidelines

20. **Warranties and Obligations:** LICENSOR further represents and warrants that, to the best of its knowledge and belief, LICENSEE's contemplated use of the Content as represented to LICENSOR does not infringe any valid rights to any third party.

21. **Breach:** If LICENSEE fails to comply with any provisions of this agreement, LICENSOR may serve written notice of breach of LICENSEE and, unless such breach is fully cured within fifteen (15) days from the receipt of notice by LICENSEE, LICENSOR may thereupon, at its option, serve notice of cancellation on LICENSEE, whereupon this Agreement shall immediately terminate.

22. **Assignment:** License conveyed hereunder by the LICENSOR shall not be assigned or granted in any manner conveyed to any third party by the LICENSEE without the consent in writing to the LICENSOR.

23. **Governing Law:** The laws of The State of New York shall govern interpretation of this Agreement and all rights and liabilities arising hereunder.

24. **Unlawful:** If any provision of this Agreement shall be found unlawful or otherwise legally unenforceable, all other conditions and provisions of this Agreement shall remain in full force and effect.

For Copyright Clearance Center / RightsLink Only:

1. **Service Description for Content Services:** Subject to these terms of use, any terms set forth on the particular order, and payment of the applicable fee, you may make the following uses of the ordered materials:

i. **Content Rental:** You may access and view a single electronic copy of the materials ordered for the time period designated at the time the order is placed. Access to the materials will be provided through a dedicated content viewer or other portal, and access will be discontinued upon expiration of the designated time period. An order for Content Rental does not include any rights to print, download, save, create additional copies, to distribute or to reuse in any way the full text or parts of the materials.

ii. **Content Purchase:** You may access and download a single electronic copy of the materials ordered. Copies will be provided by email or by such other means as publisher may make available from time to time. An order for Content Purchase does not include any rights to create additional copies or to distribute copies of the materials

Other Terms and Conditions:

v1.18

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.

Table 1. The Most Common Hereditary Sensory Autonomic Neuropathies: Clinical Features and Inheritance

Hereditary Sensory Autonomic Neuropathy (HSAN)	Onset	Inheritance	Sensory	Motor	Autonomic	Allied Features
HSAN I	Juvenile to adult	AD	Marked	Minimal	Minimal	Foot ulcers or amputations; bone deformities and osteomyelitis; hearing loss occurs occasionally
HSAN II	Childhood	AR	Marked	Minimal	Absent or minimal	Some patients develop ulcers, atrophy, and hyporeflexia
HSAN III/ Familial dysautonomia	Congenital	AR	Modest	Absent	Marked

Autonomic crises | Recurrent pneumonias; absence of tears |

			Decreased sensitivity to pain and temperature			
HSAN IV	Congenital/ childhood	AR	Modest Congenital sensory loss affecting perception of pain and temperature	Absent	Modest Anhidrosis	Oral self-mutilation; fingertip biting; repeated bone fractures and joint trauma
HSAN V	Early childhood to adult	AR	Modest Congenital reduced pain and anhidrosis	Absent	Minimal Sweating normal or reduced	Charcot joints and fracture

HSAN, Hereditary Sensory Autonomic Neuropathy; AD, autosomal dominant; AR, autosomal recessive.

From Iodice V, Sandroni P. Autonomic neuropathies. Continuum (Minneap Minn) 2014;20(5 Peripheral Nervous System

Disorders):1373-1397. Reproduced in its original format by written permission from Wolters Kluwer Health

Table 2. Other causes of autonomic neuropathy

Etiology	Onset	Sensory	Motor	Autonomic	Associated findings	Interventions
Toxic						
Chronic alcohol[79,80]	Chronic	Most common	Can present, dependent on total lifetime dose	Reduced HR variability, reduced expiratory/inspiratory ratio	Parasympathetic impairment correlates with total lifetime dose	Drug discontinuation
Vincristine[81]	Acute	Painful paresthesias	Can develop wrist extensor and toe extensor weakness	Orthostatic hypotension, urine retention, constipation (but not common)	Neurotoxicity develops at cumulative dose of 5-15mg/m^2	Drug withdrawal
Cisplatin[82,83]	Acute	Can be moderate to severe – sometimes a sensory ganglionopathy	Minimal	Orthostatic hypotension, ileus. One series showed no autonomic involvement[83]	Neurotoxicity develops at cumulative dose 200-400mg/m^2. Coasting phenomenon. Painful	Drug withdrawal
Amiodarone[84]	Acute	Moderate to severe	Moderate to severe	Orthostatic hypotension	Sural nerve biopsy shows lamellated inclusion bodies	Drug withdrawal
Infectious						
Botulism[85]	Acute	Minimal	Ptosis, dysphagia, extraocular weakness.	Cholinergic failure – dry eye, dry mouth, mydriasis, urine retention	Low CMAPs on NCS. High frequency RNS shows increment	Supportive, antitoxin

Etiology	Onset	Sensory	Motor	Autonomic	Associated findings	Interventions
Leprosy[86]	Acute/ Subacute	Length-independent sensory loss pattern	Minimal	Focal anhidrosis, loss of skin temperature regulation, vasomotor dysfunction, erectile dysfunction, cardiac autonomic neuropathy	Cutaneous, temperature-dependent damage can damage face, iris, and scalp. Can have nerve enlargement. Most cases in India.	For Paucibacillary – dapsone + rifampin For Multibacillary – dapsone, rifampin, and clofazimine
Chagas' disease[87]	Acute/ Subacute	Mild	Minimal	Palpitations, syncope, orthostatic hypotension; GI dysmotility varies from mild to severe megacolon and megaesophagus	GI pathology – submucosal and mesenteric plexus denervation. Benznidazole itself can cause peripheral neuropathy. Predominantly in South America.	Anti-parasitic therapy - benznidazole and nifurtimox
Hepatitis C virus[88,89]	Chronic	Can occur, axonal	Can occur, axonal	Baroreflex sensitivity and cardiac vagal impairment present	-	Antiviral therapy
Autoimmune						
Celiac[90]	Chronic	Small fiber predominant	Minimal	Syncope, palpitations, nausea. Cardiac vagal and sympathetic impairment	Cerebellar ataxia	Gluten-free diet

Etiology	Onset	Sensory	Motor	Autonomic	Associated findings	Interventions
Small fiber neuropathy						
Small fiber neuropathy – anhidrosis and ulcers[91,92]	Chronic	Temperature loss, pain insensitivity	Absent	QSART abnormalities in up to 75%, cardiac vagal in up to 63%, and orthostatic hypotension in up to 42%		Reversal of cause

HR, heart rate; CMAP, compound muscle action potential; NCS, nerve conduction studies; RNS, repetitive nerve stimulation.